IRLAB Therapeutics AB (OSTO:IRLAB A) Total Stockholders Equity : kr76.75 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Total Stockholders Equity?

IRLAB Therapeutics AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr76.75 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. IRLAB Therapeutics AB's Book Value per Share for the quarter that ended in Mar. 2024 was kr1.48. The ratio of a company's debt over equity can be used to measure how leveraged this company is. IRLAB Therapeutics AB's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.36.

IRLAB Therapeutics AB Total Stockholders Equity Historical Data

The historical data trend for IRLAB Therapeutics AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Total Stockholders Equity Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

181.83

347.88

399.48

290.83

115.76

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															231.28	186.37	147.98	115.76	76.75

IRLAB Therapeutics AB (OSTO:IRLAB A) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

IRLAB Therapeutics AB's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(76.745	-	0)	/	51.9482
	=	1.48

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

IRLAB Therapeutics AB's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.067	+	25.54)	/	76.745
	=	0.36

IRLAB Therapeutics AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines